SCHEMBL12845448

SCHEMBL12845448

CCOCc1cc(Nc2ccc(NCCc3c[nH]c4ccccc34)cc2)ccn1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HRH3 Q9Y5N1 4/20 0.50
HTR2A P28223 3/20 0.45
HTR1A P08908 2/20 0.45
DRD2 P14416 2/20 0.45
HTR7 P34969 1/20 0.45
HTR6 P50406 1/20 0.45
PAK4 O96013 1/20 0.44
CDK2 P24941 4/20 0.43
KMT2A Q03164 3/20 0.43
MEN1 O00255 2/20 0.43
KDM4E B2RXH2 1/20 0.43
ALDH1A1 P00352 1/20 0.43
HTT P42858 1/20 0.43
EIF2AK2 P19525 1/20 0.43
POLB P06746 1/20 0.43
SLC2A1 P11166 1/20 0.43
RAD52 P43351 1/20 0.43
PTGS2 P35354 3/20 0.42
DRD3 P35462 1/20 0.42
CCNT1 O60563 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12845461 0.95 HRH3 (0.48) HRH3HTR2AHTR1ADRD2HTR7
SCHEMBL12845611 0.90 HRH3 (0.49) HRH3HTR2AHTR1ADRD2HTR7
SCHEMBL12845641 0.90 HRH3 (0.46) HRH3HTR2AHTR1ADRD2HTR7
SCHEMBL12845458 0.90 HRH3 (0.47) HRH3HTR2AHTR1ADRD2HTR7
SCHEMBL12845428 0.89 HRH3 (0.44) HRH3HTR2AHTR1ADRD2HTR7
SCHEMBL12845595 0.87 CDK2 (0.48) HRH3PAK4CDK2POLBPTGS2
SCHEMBL12845542 0.86 HRH3 (0.44) HRH3HTR2AHTR1ADRD2HTR7
SCHEMBL12845701 0.86 CDK2 (0.48) HRH3CDK2KMT2AMEN1POLB
SCHEMBL8264799 0.86 CDK2 (0.47) HRH3PAK4CDK2POLBPTGS2
SCHEMBL12845622 0.85 HTR2A (0.53) HRH3HTR2AHTR1ADRD2HTR7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8404683-B2 Inhibitors of the interaction between MDM2 and P53 JANSSEN PHARMACEUTICAL N.V. (BE) 2013-03-26 US disclosed
US-20110053937-A1 Inhibitors of the Interaction Between MDM2 and P53 LACRAMPE JEAN FERNAND ARMAND 2011-03-03 US disclosed
US-7834016-B2 Inhibitors of the interaction between MDM2 and p53 JANSSEN PHARMACEUTICA NV (BE) 2010-11-16 US disclosed
US-7834016-B2 Inhibitors of the interaction between MDM2 and p53 JANSSEN PHARMACEUTICA NV (BE) 2010-11-16 US disclosed
US-20080039472-A1 Inhibitors of the Interaction Between Mdm2 and P53 JANSSEN PHARMACEUTICA N.V. (BE) 2008-02-14 US disclosed
US-20080039472-A1 Inhibitors of the Interaction Between Mdm2 and P53 JANSSEN PHARMACEUTICA N.V. (BE) 2008-02-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110053937-A1 Inhibitors of the Interaction Between MDM2 and P53 TP53, MDM2, TP53BP1 HRH3 3525/4885HTR2A 3566/4885HTR1A 2841/4885
US-20080039472-A1 Inhibitors of the Interaction Between Mdm2 and P53 TP53, MDM2, TP53BP1 HRH3 3525/4885HTR2A 3566/4885HTR1A 2841/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.